The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease

Therapeutic Advances in Urology

Volumn 3, Issue 5, 2011, Pages 223-232

  Damiano, Rocco ^a   Cicione, Antonio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

glycosaminoglycan; hyaluronic acid; sodium chondroitin sulphate; urothelium

Indexed keywords

CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HYALURONIC ACID; PLACEBO;

BLADDER DISEASE; BLADDER FUNCTION; CHEMICAL CYSTITIS; CYSTITIS; DRUG EFFICACY; HUMAN; INTERSTITIAL CYSTITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; SYSTEMATIC REVIEW (TOPIC); URINARY TRACT INFECTION;

EID: 80054847103     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287211418723     Document Type: Review

References (37)

1. Abrams P. Cardozo L. Fall M. Griffiths D. Rosier P. Ulmsten R. (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21: 167–178.
2. Ahmad I. Sarath Krishna N. Meddings R.N. (2008) Sequential hydrodistension and intravesical instillation of hyaluronic acid under general anaesthesia for treatment of refractory interstitial cystitis: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 19: 543–546.
3. Arms L. Vizzard M.A. (2011) Neuropeptides in lower urinary tract function. Handb Exp Pharmacol 202: 395–423.
4. Bassi P.F. Volpe A. D'Agostino D. Palermo G. Renier D. Franchini S.M. (2011) Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette–Guérin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol 185: 445–449.
5. Cervigni M. Natale F. Nasta L. Padoa A. Voi R.L. Porru D. (2008) A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 19: 943–947.
6. Clemens J.Q. (2010) Afferent neurourology: a novel paradigm. Neurourol Urodyn 29(Suppl. 1): S29–S31.
7. Constantinides C. Manousakas T. Nikolopoulos P. Stanitsas A. Haritopoulos K. Giannopoulos A. (2004) Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int 93: 1262–1266.
8. Daha L.K. Riedl C.R. Lazar D. Hohlbrugger G. Pflüger H. (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47: 393–397.
9. Damiano R. Quarto G. Bava I. Ucciero G. Palumbo M.I. Autorino R. (2011) Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol 59: 645–651.
10. Drake M.J. Nixon P.M. Crew J.P. (1998) Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf 19: 45–55.
11. Ferrara P. Marrone G. Mastrangelo A. Nicoletti A. Emmanuele V. Fasano A. (2007) Increased excretion of glycosaminoglycans in children with urinary incontinence compared to those with monosymptomatic nocturnal enuresis. Scand J Urol Nephrol 41: 218–222.
12. Foxman B. (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113(Suppl. 1A): 5S–13S.
13. Foxman B. Gillespie B. Koopman J. Zhang L. Palin K. Tallman P. (2000) Risk factors for second urinary tract infection among college women. Am J Epidemiol 51: 1194–1205.
14. Geppetti P. Nassini R. Materazzi S. Benemei S. (2008) The concept of neurogenic inflammation. BJU Int 101(Suppl. 3): 2–6.
15. Gupta S.K. Pidcock L. Parr N.J. (2005) The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU Int 96: 1063–1066.
16. Hanno P.M. Burks D.A. Clemens J.K. Dmochowski R.R. Ericksen D. Fitzgerald M.P. (2011) Cystoscopy under anesthesia with hydrodistension. In: Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. AUA Guidelines American Urological Association: Linthicum, MD.
17. Hautmann S. Toma M. Lorenzo Gomez M.F. Friedrich M.G. Jaekel T. Michl U. Schroeder G.L. (2004) Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 46: 466–471.
18. Iavazzo C. Athanasiou S. Pitsouni E. Falagas M.E. (2007) Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 51: 1534–1541.
19. Jones C.A. Nyberg L. (1997) Epidemiology of interstitial cystitis. Urology 49(Suppl. 5A): 2–9.
20. Kallestrup E.B. Jorgensen S.S. Nordling J. Hald T. (2005) Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 39: 143–147.
21. Kanai A.J. (2011) Afferent mechanism in the urinary tract. Handb Exp Pharmacol 202: 171–205.
22. Leppilahti M. Hellström P. Tammela T.L. (2002) Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 60: 46–51.
23. Lilly J.D. Parsons C.L. (1990) Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet 171: 493–496.
24. Lipovac M. Kurz C. Reithmayr F. Verhoeven H.C. Huber J.C. Imhof M. (2007) Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 96: 192–195.
25. Parsons C.L. (1994) The therapeutic role of sulfated polysaccharides in urinary bladder. Urol Clin North Am 21: 93–100.
26. Parsons C.L. (2011) The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU Int 107: 370–375.
27. Riedl C.R. Engelhardt P.F. Daha K.L. Morakis N. Pflüger H. (2008) Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 19: 717–721.
28. Samper Ots P.M. Carrizosa C.L. Rodriguez A. de Dios Saez J. Delgado J.M. de Miguel M.M. (2009) Vesical instillations of hyaluronic acid to reduce the acute vesical toxicity caused by high-dose brachytherapy do not affect the survival: a five-year follow-up study. Clin Transl Oncol 11: 828–834.
29. Shao Y. Shen Z.J. Rui W.B. Zhou W.L. (2010) Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology 75: 547–550.
30. Siracusano S. Cucchi A. Ciciliato S. Lampropoulou N. Vittur F. (2009) Urinary levels of glycosaminoglycans in patients with idiopathic detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 20: 1477–1480.
31. Sironen R.K. Tammi M. Tammi R. Auvinen P.K. Anttila M. Kosma V.M. (2011) Hyaluronan in human malignancies. Exp Cell Res 15: 383–391.
32. Soler R. Bruschini H. Martins J.R. Dreyfuss J.L. Camara N.O. Alves M.T. (2008) Urinary glycosaminoglycans as biomarker for urothelial injury: is it possible to discriminate damage from recovery? Urology 72: 937–942.
33. Sommariva M.L. Sandri S.D. Guerrer C.S. (2010) Treatment of acute iatrogenic cystitis secondary to bladder chemo-immuno-instillation or pelvic radiotherapy. Urologia 77: 187–192.
34. Tammi R.H. Kultti A. Kosma V.M. Pirinen R. Auvinen P. Tammi M.I. (2008) Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 18: 288–295.
35. Theocharis A.D. Skandalis S.S. Tzanakakis G.N. Karamanos N.K. (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277: 3904–3923.
36. Theoharides T.C. Kempuraj D. Vakali S. Sant G.R. (2008) Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek – an oral multi-agent natural supplement. Can J Urol 15: 4410–4414.
37. van de Merwe J.P. Nordling J. Bouchelouche P. Bouchelouche K. Cervigni M. Daha L.K. (2008) Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 53: 60–67.